Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9233909 | 0.86 | LOXL2 (0.51) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL1773348 | 0.86 | LOXL2 (0.51) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL8992964 | 0.85 | MAPT (0.56) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL70372 | 0.84 | TSHR (0.57) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL2579068 | 0.84 | KEAP1 (0.56) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL9234838 | 0.83 | RAB9A (0.52) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL305693 | 0.83 | LOXL2 (0.56) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL481297 | 0.81 | LOXL2 (0.61) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL6158387 | 0.81 | TSHR (0.67) | LOXL2CYP4A11TSHRCYP4F2CA1 | |
| SCHEMBL1774704 | 0.81 | PKM (0.47) | LOXL2CYP4A11TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| WO-2009097997-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | LOXL2 2751/4885CYP4A11 261/4885TSHR 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.